REVIEW
Intralesional corticosteroid treatment of multiple eruptive keratoacanthomas: case report and review of a controversial therapy.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.] 2002 October
BACKGROUND: Use of intralesional corticosteroids in the management of keratoacanthomas has been reported in older literature. Yet this therapy is no longer a commonly considered treatment option.
OBJECTIVE: To report management of a therapeutically challenging patient with multiple eruptive keratoacanthomas with intralesional corticosteriod treatment to revive awareness of this treatment option.
METHODS: A 55-year-old female with frequent episodes of multiple eruptive keratoacanthomas was treated with intralesional corticosteroids and methotrexate.
RESULTS: Intralesional corticosteroids successfully treated eruptive keratoacanthomas with complete regression and minimal scarring within 2-4 weeks.
CONCLUSION: Despite its limitations, intralesional corticosteroids may have a role in the treatment of select keratoacanthomas.
OBJECTIVE: To report management of a therapeutically challenging patient with multiple eruptive keratoacanthomas with intralesional corticosteriod treatment to revive awareness of this treatment option.
METHODS: A 55-year-old female with frequent episodes of multiple eruptive keratoacanthomas was treated with intralesional corticosteroids and methotrexate.
RESULTS: Intralesional corticosteroids successfully treated eruptive keratoacanthomas with complete regression and minimal scarring within 2-4 weeks.
CONCLUSION: Despite its limitations, intralesional corticosteroids may have a role in the treatment of select keratoacanthomas.
Full text links
Trending Papers
Mechanical power of ventilation and driving pressure: two undervalued parameters for pre extracorporeal membrane oxygenation ventilation and during daily management?Critical Care : the Official Journal of the Critical Care Forum 2023 March 15
Practical guide for safe sedation.Journal of Anesthesia 2023 March 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app